基于结构的生物活性植物化学物质的识别,以向与kallikrein相关的化酶2用于前列腺癌治疗
Deeba Shamim Jairajpuri1, Afzal Hussain2, Mohamed F Alajmi2
1Department of Medical Biochemistry, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain.
Frontiers in chemistry
|April 10, 2025
概括
研究人员确定了三个天然化合物,Phaseolin,Withaphysalin D和Nicandrenone,作为前列腺癌中与Kallikrein相关的酶2 (KLK2) 的潜在抑制剂. 这些植物化学物质显示出开发新向疗法的前景.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡利克林相关酶2 (KLK2) 是前列腺癌中过度表达的血清蛋白酶,有助于癌症的进展.
- KLK2的抗血管性质和癌症中的作用使其成为一个重要的治疗点.
- 现有的KLK2小分子抑制剂在特异性,选择性和临床进步方面面临挑战.
研究的目的:
- 通过基于结构的虚拟查来识别KLK2的新型植物化学抑制剂.
- 研究潜在KLK2抑制剂的结合相互作用和结合机制.
- 为开发前列腺癌的新向疗法提供基础.
主要方法:
- 一个植物化学库的基于结构的虚拟选.
- 分子对接研究,以评估与KLK2的结合 afinities 和相互作用.
- 分子力学与Poisson-Boltzmann表面积 (MM-PBSA) 计算用于自由能量验证.
主要成果:
- 确定了三种潜在的KLK2抑制剂:法索林,维他菲萨林D和尼坎德伦.
- 这些化合物表现出高结合亲和度 (-8.9到-8.8 kcal/mol) 和与KLK2催化残留的稳定相互作用.
- MM-PBSA的计算证实了已识别的植物化学物质与KLK2的能量有利结合.
结论:
- 费索林,维他菲萨林D和尼坎德伦显示出作为新型KLK2抑制剂的显著潜力.
- 这些植物化学物质为开发具有提高疗效的向前列腺癌治疗提供了有希望的途径.
- 这项研究强调了植物化学库和虚拟查在癌症药物发现中的实用性.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


